Status:
TERMINATED
Extension Study of Participants From SPG302-ALS-001
Lead Sponsor:
Spinogenix
Conditions:
Amyotrophic Lateral Sclerosis (ALS)
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
Detailed Description
This is an open-label extension study of SPG302-ALS-001 to investigate the long-term safety, tolerability, and efficacy of SPG302 administered orally in participants with Amyotrophic Lateral Sclerosis...
Eligibility Criteria
Inclusion
- • Must have participated in all study activities of SPG302-ALS-001, the parent study
Exclusion
- Unable to reliably and regularly swallow whole oral medications on a daily basis.
- Medical conditions that investigator or sponsor determine would interfere with participation in clinical trial
Key Trial Info
Start Date :
May 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06903286
Start Date
May 29 2025
End Date
August 31 2025
Last Update
December 17 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Macquarie University
North Ryde, New South Wales, Australia, 2109
2
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia, 4029
3
Flinders Medical Center
Adelaide, South Australia, Australia, 5042